C-Pharma - new company focused on development of Hepatitis C products

Cyplasin Biomedical Ltd Announces Name Change And Creation of a Subsidiary C-Pharma Inc.
EDMONTON, March 29 /CNW/ - Cyplasin Biomedical is a product-oriented, specialty pharmaceutical company focused on developing products for multi-billion dollar markets. The Company is pleased to announce that in order to better reflect multiple new product development opportunities and to continue its current product development programs for Hepatitis C; will effective immediately, change its name to Compass Biotechnologies Inc., and will continue to be traded on the OTC Link exchange under a new trading symbol "COBI".

Compass Biotechnologies Inc., plans on developing several new technologies and revenue generating products and through its wholly owned subsidiary C-Pharma, continue to finance and develop the previously announced Hepatitis C products.

Compass CEO Garth Likes commented, "The creation of C-Pharma to focus solely on the current and future Hepatitis franchise creates a dedicated focus AND VALUE for our shareholders. Compass Biotechnologies will in parallel be able to take advantage of several new and complementary technologies and products that will further add increased value. The new product opportunities within Compass will be announced in the near future as the various components of the project are finalized."

Shareholders of the previously named company "Cyplasin" will be able to physically exchange their share certificates for "Compass" certificates by contacting the Company's transfer agent Pacific Stock Transfer. Detailed exchange instructions will be posted on our website www.c-pharma.net in the next few days.

ABOUT Compass Biotechnology Inc and its wholly owned subsidiary C-Pharma Inc : http://www.c-pharma.net/

Compass Biotechnologies Inc., is a publically-traded specialty pharmaceutical company (OTCQB:COBI) with headquarters in Edmonton, Alberta.

C-PHARMA Inc has amassed a portfolio of key products for the treatment and prevention of HCV infection, which affects over 4 million people in the U.S. and several hundred million people worldwide.

C-Pharma's technology encompasses the use of recombinant DNA technology to manufacture recombinant cytokines and virus like particles (VLPs). VLPs can be engineered to incorporate various viral and non-viral antigens for use as vaccines against many different types of targets such as hepatitis C. C-Pharma is using the technology to develop a hepatitis C vaccine ( C- Vaxin) to prevent hepatitis C viral infection. The Company is also pursuing a revenue generation strategy by commercializing highly profitable therapeutic drugs (C-Virin & C-Pegferon) for use in the hepatitis C market.